Infusions & Injections

ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of rheumatoid arthritis (RA), giant cell arthritis (GCA), systemic sclerosis-associated interstitial lung disease (SSc-ILD), polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA), and cytokine release syndrome (CRS). This medication is available as an infusion or a subcutaneous injection.

ALYMSYS® (bevacizumab-maly) is an FDA-approved biosimilar to AVASTIN®, given as an intravenous infusion. This VEGF inhibitor is used in combination with chemotherapy or interferon alfa for metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

AMVUTTRA® (vutrisiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This medication targets the transthyretin (TTR) gene to reduce the production of abnormal TTR protein, which can accumulate in tissues and cause damage in patients with hATTR. AMVUTTRA is administered as a subcutaneous injection once every three months, offering a long-acting treatment option for managing this progressive condition.

Apretude® (cabotegravir extended-release injectable suspension) is an FDA-approved pre-exposure prophylaxis (PrEP) medication used to reduce the risk of sexually acquired HIV-1 in eligible HIV-negative adults and adolescents weighing at least 35 kg (77 lbs). Administered as an intramuscular injection every two months following the initial doses, Apretude offers a long-acting alternative to daily oral PrEP medication.

ARANESP® (darbepoetin alfa) is an FDA-approved erythropoiesis-stimulating agent given by subcutaneous or intravenous injection for anemia due to chronic kidney disease and for anemia caused by myelosuppressive chemotherapy in adults with non-myeloid cancers.

AVASTIN® (bevacizumab) is an FDA-approved VEGF inhibitor given as an intravenous infusion, used in combination with chemotherapy or other therapies for metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, and hepatocellular carcinoma.

AVSOLA® (infliximab-axxq) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis

BENLYSTA® (belimumab) is a B-lymphocyte stimulator (BLyS) inhibitor indicated for the treatment of systemic lupus erythematosus (SLE) in autoantibody-positive adult patients, and active lupus nephritis

BONIVA® (ibrandronate sodium) is an infusion therapy FDA-approved for the treatment and prevention of postmenopausal osteoporosis.

BRUIMVI® (brucemizumab) is a monoclonal antibody therapeutic indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This medication targets the CD20 protein on the surface of B-cells, a type of immune cell that plays a role in the autoimmune process underlying MS. By depleting these B-cells, BRUIMVI helps to reduce inflammation and prevent the progression of disability associated with MS. BRUIMVI is administered as an intravenous infusion, typically given every 6 months after an initial loading phase, offering a long-acting treatment option for managing this chronic neuroinflammatory disease.